Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

Lanza, Frank L.; Hunt, Richard H.; Thomson, A. B. R.; Provenza, J. Mark; Blank, Marion

doi:10.1053/gast.2000.16517

Cited by 176 publications

(76 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There exists some evidence that branded Risedronate might be a slightly better suitable alternative bisphosphonate drug for gastrointestinal sensitive patients compared to original branded or generic Alendronate [7][8][9]32,33,[39][40][41][42][43][44][45][46]. Two recent studies have shown differences in tablets properties that might explain different rates of adverse events.…”

Section: Lower Bioavailability and Higher Rate Of Adverse Events Due mentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

Section: Lower Bioavailability and Higher Rate Of Adverse Events Due mentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

“…Generally, these gastrointestinal sideeffects were attributed to high local concentrations of the drug in patients who did not follow dosing instructions properly, or to their having an underlying esophageal or gastric disease (Lanza et al 1998, Lowe et al 2000, Graham 2002). Moreover, two large clinical studies revealed that when standard doses of bisphosphonates were administered in the proper manner in female volunteers without gastrointestinal symptoms or initial endoscopic pathology, erosions and ulceration in both the stomach and duodenum developed (Lanza et al 2000, Thomson et al 2002.…”

Section: Introductionmentioning

confidence: 99%

Ghrelin against alendronate-induced gastric damage in rats

İşeri

Şener²,

Yüksel³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

Alendronate sodium, a primary amino bisphosphonate, is widely used in the treatment of various diseases that are associated with bone resorption, such as postmenopausal osteoporosis and Paget's disease of bone. Although the adverse effects of biphosphonates on the gastrointestinal system have been demonstrated in experimental and clinical studies, the exact mechanisms underlying this damage are not clear yet. Ghrelin, a 28 amino acid peptide produced predominantly by the stomach, was shown to exert a potent protective action on the stomach of rats exposed to ethanol or stress.Our objective was to evaluate the possible antioxidant and anti-inflammatory effects of ghrelin against alendronate-induced gastric damage. Wistar albino rats were administered alendronate (20 mg/kg) by gavage for 4 days, along with either ghrelin (10 ng/kg per day) or saline given i.p. After decapitation, stomach tissues were removed for the determination of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity and tissue collagen content, while the extent of tissue damage was analyzed microscopically. Formation of reactive oxygen species was determined by chemiluminesence using a luminol probe in fresh gastric tissues. Serum tumor necrosis factor (TNF-) and lactate dehydrogenase levels were assessed in trunk blood.Oral administration of alendronate-induced significant gastric damage, accompanied by increased MPO activity, collagen content, MDA and luminol levels (P<0·01-P<0·001), while tissue GSH was decreased (P<0·01). On the other hand, ghrelin treatment reversed these alterations (P<0·05-P<0·001) as well as elevating serum TNF-levels significantly (P<0·001).The findings of the present study suggest that alendronate induces oxidative gastric damage by a local irritant effect, and ghrelin ameliorates this damage by its possible antioxidant and anti-inflammatory properties.

show abstract

“…Finally, n values equal to or higher than 0.85 correspond to a case II transport (relaxation controlled delivery). 32 (4) In all cases the fit was carried out using the Scientist 2.0 software (Micromath, USA). The selection of the model was based on the best correlation coefficient and the best model selection criteria (MSC), both provided by the software, and the best graphic adjustment.…”

Section: Mathematical Modelingmentioning

confidence: 99%

“…1,2 However, sodium alendronate oral administration is associated with adverse gastrointestinal events such as gastroesophageal inflammation and ulceration, esophageal erosions and gastrointestinal bleeding. [3][4][5] The low oral bioavailability of sodium alendronate (less than 1%) is attributed to its poor lipophilicity, which prevents transcellular transport across the epithelial barriers. 2 Among the different strategies to circumvent the low bioavailability of drugs, the microencapsulation is one of the most important.…”

Section: Introductionmentioning

confidence: 99%

High encapsulation efficiency of sodium alendronate in eudragit S100/HPMC blend microparticles

Cruz¹,

Assumpção²,

Guterres³

et al. 2009

Quím. Nova

View full text Add to dashboard Cite

Recebido em 16/5/08; aceito em 12/12/08; publicado na web em 11/5/09The hydrophilic drug sodium alendronate was encapsulated in blended microparticles of Eudragit ® S100 and Methocel ® F4M or Methocel ® K100LV. Both formulations prepared by spray-drying showed spherical collapsed shape and smooth surface, encapsulation efficiencies of 85 and 82% and mean diameters of 11.7 and 8.4 µm, respectively. At pH 1.2, in vitro dissolution studies showed good gastro-resistance for both formulations. At pH 6.8, the sodium alendronate release from the microparticles was delayed and was controlled by Fickian diffusion. In conclusion, the prepared microparticles showed high encapsulation efficiency of sodium alendronate presenting gastro-resistance and sustained release suitable for its oral administration.

show abstract

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

Cited by 176 publications

References 26 publications

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ghrelin against alendronate-induced gastric damage in rats

High encapsulation efficiency of sodium alendronate in eudragit S100/HPMC blend microparticles

Contact Info

Product

Resources

About